Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Reata Pharmaceuticals stock | 170.4

Own Reata Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Reata Pharmaceuticals, Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 220 staff and has a trailing 12-month revenue of around USD$8.5 million.

How to buy shares in Reata Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Reata Pharmaceuticals. Find the stock by name or ticker symbol: RETA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Reata Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$170.4, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Reata Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Reata Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Reata Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Reata Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$170.4, which is 19.30% down on its pre-crash value of USD$211.14 and 50.78% up on the lowest point reached during the March crash when the shares fell as low as USD$113.01.

If you had bought USD$1,000 worth of Reata Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$536.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$707.16.

Reata Pharmaceuticals share price

Use our graph to track the performance of RETA stocks over time.

Reata Pharmaceuticals shares at a glance

Information last updated 2020-11-26.
Latest market close USD$170.4
52-week range USD$88.17 - USD$257.965
50-day moving average USD$135.3817
200-day moving average USD$134.5608
Wall St. target price USD$245.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.056

Buy Reata Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Reata Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Reata Pharmaceuticals price performance over time

Historical closes compared with the close of $170.4 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-30) 46.00%
3 months (2020-08-26) N/A
6 months (2020-05-26) N/A
1 year (2019-11-26) N/A
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Reata Pharmaceuticals financials

Revenue TTM USD$8.5 million
Gross profit TTM USD$-225,990,000
Return on assets TTM -49.7%
Return on equity TTM -623.06%
Profit margin 0%
Book value $5.486
Market capitalisation USD$5.1 billion

TTM: trailing 12 months

Shorting Reata Pharmaceuticals shares

There are currently 3.1 million Reata Pharmaceuticals shares held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 8.5% down from 3.4 million last month.

There are a few different ways that this level of interest in shorting Reata Pharmaceuticals shares can be evaluated.

Reata Pharmaceuticals's "short interest ratio" (SIR)

Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals shares currently shorted divided by the average quantity of Reata Pharmaceuticals shares traded daily (recently around 265630.23850085). Reata Pharmaceuticals's SIR currently stands at 11.74. In other words for every 100,000 Reata Pharmaceuticals shares traded daily on the market, roughly 11740 shares are currently held short.

However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals shares, or, against the total number of tradable Reata Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Reata Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.1448% of the tradable shares (for every 100,000 tradable Reata Pharmaceuticals shares, roughly 145 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Reata Pharmaceuticals.

Find out more about how you can short Reata Pharmaceuticals stock.

Reata Pharmaceuticals share dividends

We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.

Reata Pharmaceuticals share price volatility

Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $88.17 up to $257.965. A popular way to gauge a stock's volatility is its "beta".

RETA.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5686. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Reata Pharmaceuticals overview

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site